BioSpace News Archive

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will be participating at three upcoming investor conferences.

Tenon Medical, Inc. today announced the Company will participate in The Benchmark Company Healthcare House Call Virtual 1x1 Investor Conference on Thursday, June 2, 2022.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Health (NIH) Intramural Research Program-sponsored study titled “An Observational Study of Neurologic Function after COVID-19 Infection” utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology.

Arcutis Biotherapeutics, Inc. announced results of a nationwide survey of adults with seborrheic dermatitis and the healthcare providers that treat them, designed to better understand their satisfaction and experience with currently available treatment options.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Ghryvelin ™ (macimorelin), the first oral test approved for diagnosing Growth Hormone Deficiency in adults (AGHD), is now available to healthcare professionals across Europe (subject to reimbursement).

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H. C. Wainwright Global Investment Conference 2022, a hybrid in-person/ virtual conference being held May 23rd through 26th , 2022.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced its management team will host a conference call following two poster presentations of PDS0101 data at 2022 American Society of Clinical Oncology Meeting (ASCO).

Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa and to advance in vivo candidate for hereditary tyrosinemia type 1 towards IND application.